Life Sciences: What's new in France?
May 18, 2021
Read more about the recent developments in the life sciences sector in France.
Content:
- The EU’s action plan on Intellectual Property after Covid-19
- Negotiation and mediation: How life sciences companies can institutionalize the use of these tools during the pandemic and beyond
- Reshaping early access programs: Simplification, but strengthening of eligibility
- The Aspen case: the Commission issues its first decision relating to excessive pricing in the pharmaceutical sector
- “Pay-for-Delay”: the European Court of Justice confirms the anticompetitive nature of Lundbeck’s reverse payment patent
- French Administrative Supreme Court extends pharmacies’ capacities to compete online in the EU market
- Adoption of the new framework agreement governing the setting and regulation of prices of medicinal products: Despite ambitious objectives, an implementation to watch
Related Professionals
